Scholarlink

Purpose <p>To identify the predictive role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) for long-term outcomes in non-small cell lung cancer (NSCLC) patients.</p> Methods <p>Several databases were searched. The primary outcome was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analyses based on the time point of MRD detection (landmark vs. longitudinal) and treatment (surgery vs. chemoradiotherapy) were further performed.</p> Results <p>Ten studies with 1859 cases were included. Pooled results demonstrated that positive ctDNA MRD significantly predicted worse PFS (HR = 11.19, 95% CI: 6.10–20.52, <i>P</i> &lt; 0.001), OS (HR = 6.34, 95% CI: 2.27–17.74, <i>P</i> &lt; 0.001) and CSS (HR = 16.67, 95% CI: 10.00–25.00, <i>P</i> &lt; 0.001). Subgroup analysis by the time points of MRD detection (landmark: HR = 8.93, <i>P</i> &lt; 0.001; longitudinal: HR = 17.52, <i>P</i> &lt; 0.001) and treatment (surgery: HR = 11.63, <i>P</i> &lt; 0.001; chemoradiotherapy: HR = 5.56, <i>P</i> &lt; 0.001) revealed consistent results.</p> Conclusion <p>ctDNA-based MRD could serve as a valuable prognostic indicator in NSCLC, and patients with positive ctDNA-based MRD are at significantly greater risk of recurrence and lower survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月13日

查看全文
  • Siyuan Che,
  • Dongliang Yu

摘要

Purpose

To identify the predictive role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) for long-term outcomes in non-small cell lung cancer (NSCLC) patients.

Methods

Several databases were searched. The primary outcome was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analyses based on the time point of MRD detection (landmark vs. longitudinal) and treatment (surgery vs. chemoradiotherapy) were further performed.

Results

Ten studies with 1859 cases were included. Pooled results demonstrated that positive ctDNA MRD significantly predicted worse PFS (HR = 11.19, 95% CI: 6.10–20.52, P < 0.001), OS (HR = 6.34, 95% CI: 2.27–17.74, P < 0.001) and CSS (HR = 16.67, 95% CI: 10.00–25.00, P < 0.001). Subgroup analysis by the time points of MRD detection (landmark: HR = 8.93, P < 0.001; longitudinal: HR = 17.52, P < 0.001) and treatment (surgery: HR = 11.63, P < 0.001; chemoradiotherapy: HR = 5.56, P < 0.001) revealed consistent results.

Conclusion

ctDNA-based MRD could serve as a valuable prognostic indicator in NSCLC, and patients with positive ctDNA-based MRD are at significantly greater risk of recurrence and lower survival.